Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Operating Leases (2019 - 2024)

VYNE Therapeutics' Operating Leases history spans 5 years, with the latest figure at $99000.0 for Q4 2024.

  • For Q4 2024, Operating Leases fell 53.74% year-over-year to $99000.0; the TTM value through Dec 2024 reached $99000.0, down 53.74%, while the annual FY2024 figure was $99000.0, 53.74% down from the prior year.
  • Operating Leases reached $99000.0 in Q4 2024 per VYNE's latest filing, up from $25000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.6 million in Q2 2020 to a low of $25000.0 in Q2 2024.
  • Average Operating Leases over 4 years is $927083.3, with a median of $769500.0 recorded in 2020.
  • Peak YoY movement for Operating Leases: skyrocketed 630.0% in 2020, then crashed 78.32% in 2021.
  • A 4-year view of Operating Leases shows it stood at $1.6 million in 2020, then plummeted by 78.32% to $349000.0 in 2021, then tumbled by 38.68% to $214000.0 in 2023, then plummeted by 53.74% to $99000.0 in 2024.
  • Per Business Quant, the three most recent readings for VYNE's Operating Leases are $99000.0 (Q4 2024), $25000.0 (Q2 2024), and $63000.0 (Q1 2024).